Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 16/20 | 0.41 |
| ▸ | CDK12 | Q9NYV4 | 16/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.38 |
| ▸ | NPY2R | P49146 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.37 |
| ▸ | CDK2 | P24941 | 3/20 | 0.37 |
| ▸ | CDK7 | P50613 | 3/20 | 0.37 |
| ▸ | CCNH | P51946 | 3/20 | 0.37 |
| ▸ | MNAT1 | P51948 | 3/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4227795 | 1.00 | CCNK (0.41) | CCNKCDK12PIK3CDCDK13NPY2R | |
| SCHEMBL4228042 | 0.95 | NPY2R (0.41) | CCNKCDK12NPY2RCCNA2CDK2 | |
| SCHEMBL4228045 | 0.95 | NPY2R (0.41) | CCNKCDK12NPY2RCCNA2CDK2 | |
| SCHEMBL4223896 | 0.94 | CCNK (0.42) | CCNKCDK12CDK13CCNA2CDK2 | |
| SCHEMBL4223904 | 0.94 | CCNK (0.42) | CCNKCDK12CDK13CCNA2CDK2 | |
| SCHEMBL4223279 | 0.94 | CCNK (0.43) | CCNKCDK12CCNA2CDK2CDK7 | |
| SCHEMBL4223274 | 0.94 | CCNK (0.43) | CCNKCDK12CCNA2CDK2CDK7 | |
| SCHEMBL4225299 | 0.93 | CDK12 (0.40) | CCNKCDK12CDK13CCNA2CDK2 | |
| SCHEMBL4225295 | 0.93 | CDK12 (0.40) | CCNKCDK12CDK13CCNA2CDK2 | |
| SCHEMBL4230161 | 0.92 | CCNK (0.43) | CCNKCDK12CCNA2CDK2CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557127-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20090054464-A1 | HDAC INHIBITOR | ASTELLAS PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-7465731-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2008-12-16 | — | — | US | disclosed |
| EP-1776357-A1 | HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC) | Astellas Pharma Inc. (JP) | 2007-04-25 | — | — | EP | disclosed |
| US-20060052599-A1 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2006-03-09 | — | — | US | disclosed |
| WO-2006016680-A1 | HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC) | ASTELLAS PHARMA INC. (JP) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052599-A1 | HDAC inhibitor | HDAC1, HDAC2, HDAC11 | CCNK 1593/4885CDK12 2055/4885PIK3CD 2243/4885 |
| US-20090054464-A1 | HDAC INHIBITOR | HDAC1, HDAC2, HDAC8 | CCNK 1565/4885CDK12 1720/4885PIK3CD 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.